Literature DB >> 24703892

Crizotinib and renal insufficiency: a case report and review of the literature.

Paloma Martín Martorell1, Marisol Huerta Alvaro2, Miguel A Solís Salguero3, Amelia Insa Molla2.   

Abstract

A 69 year old man with idiopathic chronic kidney disease was diagnosed with relapsing EGFR negative, ALK positive lung adenocarcinoma, and treated with chemotherapy and antiangiogenic treatment, under which his renal insufficiency worsened. During second line crizotinib treatment, further worsening of the renal function was seen, with very clear correlation with crizotinib withdrawal and rechallenge. No further drug causes for the worsening blood creatinine values were detected.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ALK; Crizotinib; Lung adenocarcinoma; Renal insufficiency; Toxicity; Tyrosine kinase inhibitors

Mesh：

Substances：

Year:  2014        PMID： 24703892     DOI： 10.1016/j.lungcan.2014.03.001

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  8 in total

Review 1.  Renal effects of targeted anticancer therapies.

Authors:  Camillo Porta; Laura Cosmai; Maurizio Gallieni; Paolo Pedrazzoli; Fabio Malberti
Journal:  Nat Rev Nephrol       Date:  2015-03-03       Impact factor: 28.314

Review 2.  The renal effects of ALK inhibitors.

Authors:  Hassan Izzedine; Rania Kheder El-Fekih; Mark A Perazella
Journal:  Invest New Drugs       Date:  2016-07-29       Impact factor: 3.850

3.  Crizotinib-induced toxicity in an experimental rat model.

Authors:  Ozge Gumusay; Guldal Esendagli-Yilmaz; Aytug Uner; Bulent Cetin; Suleyman Buyukberber; Mustafa Benekli; Mustafa N Ilhan; Ugur Coskun; Ozlem Gulbahar; Ahmet Ozet
Journal:  Wien Klin Wochenschr       Date:  2016-03-14       Impact factor: 1.704

4.  Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report.

Authors:  Shalin Kothari; Najam Ud-Din; Michele Lisi; Thomas Coyle
Journal:  J Med Case Rep       Date:  2016-06-14

Review 5.  Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.

Authors:  Kenar D Jhaveri; Rimda Wanchoo; Vipulbhai Sakhiya; Daniel W Ross; Steven Fishbane
Journal:  Kidney Int Rep       Date:  2016-09-21

6.  Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction.

Authors:  Midori Shimada; Minoru Fukuda; Masaaki Fukuda; Takeshi Kitazaki; Kohji Hashiguchi; Takaya Ikeda; Hiroyuki Yamaguchi; Katsumi Nakatomi; Kazuto Ashizawa; Hiroshi Mukae
Journal:  Onco Targets Ther       Date:  2017-06-29       Impact factor: 4.147

7.  Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment.

Authors:  Adeline Rosoux; Fabrice Duplaquet; Sebahat Ocak
Journal:  Case Rep Oncol       Date:  2017-05-16

8.  Renal Injury during Long-Term Crizotinib Therapy.

Authors:  Taro Yasuma; Tetsu Kobayashi; Corina N D'Alessandro-Gabazza; Hajime Fujimoto; Kentaro Ito; Yoichi Nishii; Kota Nishihama; Prince Baffour Tonto; Atsuro Takeshita; Masaaki Toda; Esteban C Gabazza; Osamu Taguchi; Shigenori Yonemura; Osamu Hataji
Journal:  Int J Mol Sci       Date:  2018-09-25       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.